Kisspeptin-10

Mechanism

Stimulates GnRH neurons and pulsatile LH/FSH release.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Libido support
• LH/FSH elevation
• Testicular function

Reconstitution

mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.

Half-life, storage & sport

Elimination half-life

not on file — no primary pharmacokinetic study found stating a human plasma half-life.

Storage

Lyophilised: Stable at room temperature ~3 weeks; store desiccated below -18C. Reconstituted: 4C for 2-7 days; below -18C with 0.1% HSA/BSA for long term; avoid freeze-thaw. — source. ProSpec technical datasheet. Supplier handling recommendation for research-grade lyophilate, not a per-compound stability study.

In sport (WADA 2026)

Prohibited, at all times, males only — named S2.2.1 (testosterone-stimulating peptides in males: kisspeptin and its agonist analogues). the list S2.2.1 is written for male athletes. For female athletes it is not captured by S2.2.1; kisspeptin-10 has no therapeutic approval, so S0 would then apply.

Literature on file 3

• animal in vivo
  Kisspeptin directly stimulates gonadotropin-releasing hormone release via G protein-coupled receptor 54 (Proceedings of the National Academy of Sciences 2005, cited 973x) graded on: an animal model — read from the indexed abstract — “mice”
• review or editorial
  Kisspeptin Signaling in the Brain (Endocrine Reviews 2009, cited 681x) graded on: indexed as "Review" - secondary literature, not a study — “Review”

Not graded

1 citation whose study design could not be read from the title. Left ungraded rather than guessed at.

• not graded
  NCT07224490: Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease graded on: NCT07224490 is recruiting and has posted no results - a registration, not a reported outcome — “NCT07224490”

What is circulated not evidence 4

Claims passed around in community guides and vendor copy, recorded because they circulate — not because they are true. Each is shown with the page it was read from and what this record actually holds. Checked 2026-08-24.

• unverified community data dose common agrees with the record

  A dose of about 1 mcg/kg (roughly 100 mcg) as a single injection is circulated as the point of highest LH response.

  Studies report that LH response is highest after administering a one-time dose of 1mcg/kg of body weight

  On the record The corpus dosing row holds 100-500 mcg three times weekly (raw: "100-500 mcg 3x/week"), verified: false. The record's regulatory row confirms verified human trials exist for kisspeptin-10, and 1 mcg/kg IV boluses are within the studied range — but the corpus does not hold a per-kg dose-response curve.

  Source 1

• unverified community data timing common nothing on file either way

  It is circulated that daily dosing must be avoided because continuous kisspeptin exposure desensitises the receptor and suppresses the HPG axis.

  Researchers are advised against repeated daily dosing of the peptide.

  On the record The corpus records HPG-axis stimulation via GnRH neurons and pulsatile LH/FSH release as the mechanism, which is where the desensitisation logic comes from, but the record holds no study of subcutaneous daily community-style dosing or of a suppression threshold.

  Source 1

• unverified community data benefit ubiquitous agrees with the record

  Increased LH, LH pulse frequency and testosterone in healthy males is circulated as the demonstrated benefit, extended by the community into a libido and PCT use.

  One such study found that injecting kisspeptin-10 into healthy males increased LH production, LH pulse frequency and size, and testosterone

  On the record The corpus benefits row holds libido support, LH/FSH elevation and testicular function, with verified human trial evidence recorded. The hormone-elevation part matches the record; the extension to post-cycle-therapy restart protocols has nothing on file. The record also notes WADA prohibition for male athletes (S2.2.1).

  Source 1

• unverified community data timing occasional nothing on file either way

  Timing a dose 30-60 minutes before sexual activity for a libido effect is circulated as a protocol.

  45-60 minutes after administration

  On the record Nothing on file. The corpus holds no on-demand libido timing protocol; the study context is hormone measurement, not pre-activity dosing.

  Source 1

Identity

PubChem CID 25240297 computed 3D conformer

Skeletal formulathe canonical depiction

Drawn by PubChem from CID 25240297, the identifier on this record.

Molecular weight

5857

Molecular formula

C63H83N17O14

CAS number

374675-21-5

PubChem CID

25240297

InChI key

RITKWYDZSSQNJI-INXYWQKQSA-N

Sequence

YNWNSFGLRF

SMILES

CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC5=CC=C(C=C5)O)N

InChI

InChI=1S/C63H83N17O14/c1-34(2)24-45(58(90)74-43(18-11-23-70-63(68)69)57(89)75-44(54(67)86)26-35-12-5-3-6-13-35)73-53(85)32-72-56(88)46(27-36-14-7-4-8-15-36)77-62(94)50(33-81)80-61(93)49(30-52(66)84)79-59(91)47(28-38-31-71-42-17-10-9-16-40(38)42)78-60(92)48(29-51(65)83)76-55(87)41(64)25-37-19-21-39(82)22-20-37/h3-10,12-17,19-22,31,34,41,43-50,71,81-82H,11,18,23-30,32-33,64H2,1-2H3,(H2,65,83)(H2,66,84)(H2,67,86)(H,72,88)(H,73,85)(H,74,90)(H,75,89)(H,76,87)(H,77,94)(H,78,92)(H,79,91)(H,80,93)(H4,68,69,70)/t41-,43-,44-,45-,46-,47-,48-,49-,50-/m0/s1

Classified as

HPG Axispathway

The feedback structure is why a record here may report a change in LH or FSH rather than in testosterone, and why those readings can move in opposite directions on the same page.

Subcutaneousroute

This is the route the reconstitution arithmetic assumes. Mass divided by diluent volume gives concentration, dose divided by concentration gives volume, and volume in mL multiplied by 100 gives units on a U-100 barrel: 5 mg in 2 mL is 2.5 mg/mL, and 0.25 mg comes out at 0.1 mL, which is 10 units.

Intravenousroute

A large share of the pharmacokinetic numbers attached to peptide records, half-life in particular, come from intravenous studies and often from animals. Those numbers describe an intravenous curve and do not transfer unchanged to a depot under the skin.

Also called

• Kisspeptin-10
• kisspeptin
• kisspeptin peptide

Listed prices 199

What 130 shops we track listed for Kisspeptin-10, read from their own public catalogues on 2026-09-14. We take no commission on these and they are not ranked by any payment — how vendors are scored.

Share this record